Contract Services
WuXi Biologics Breaks Ground on State-of-the-Art $1.4 Billion CRDMO Facility in Singapore
WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced ...
March 19, 2024 | News
Suven Pharmaceuticals Joins Forces with Cohance Lifesciences in Transformative Merger to Strengthen CDMO Dominance
Transformative Merger with 2x Scale and Double-Digit EPS Accretion in the first year Suven poised to become a leading integrated CDMO player...
March 01, 2024 | News
BioCina and NovaCina Join Forces for Integrated Biologics Solutions
BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), and NovaCina Pty Ltd., a global fill-and-finish...
February 28, 2024 | News
GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj
Immuncell-LC Inj. is an autologous Cytokine Induced Killer (CIK) cell therapy approved for Commercial use in South Korea as an adjuvant cell th...
February 27, 2024 | News
CATUG and Crystal Bio Launch Joint Lab for Advanced Nucleic Acid Analysis
CATUG, a distinguished global entity specializing in integrated nucleic acid and drug delivery CRDMO services, is combining capabilities with Crystal ...
February 25, 2024 | News
WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma
WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, today announced that the U.S. Food and Dr...
February 21, 2024 | News
Samsung Biologics and LegoChem Biosciences Forge Strategic Partnership for ADC Development and Manufacturing
The collaboration marks a pivotal milestone as Samsung Biologics commits to providing cutting-edge antibody development and drug substance manufact...
February 12, 2024 | News
Novo Nordisk's Investment Arm, Novo Holdings, Seals $16.5 Billion Deal to Acquire Catalent in All-Cash Transaction
Catalent, Inc. (NYSE: CTLT), a prominent player in advancing global patient treatment solutions, and Novo Holdings, a holding and investment entity oversee...
February 06, 2024 | News
WuXi Biologics Achieves Milestone with 16,000L Manufacturing Run in Ireland
First manufacturing run successful for MFG7 facility at the Ireland site Largest manufacturing scale to date achieved by combining four 4,000-liter sing...
February 01, 2024 | News
WuXi XDC Partners with Multitude and HySlink for Accelerated ADC Discovery and Development
WuXi XDC will provide a fully integrated, one-stop bioconjugate platform and end-to-end CRDMO services. As WuXi XDC's strategic partner, Multitude Therapeu...
January 31, 2024 | News
WuXi XDC and Celltrion Collaborate on Comprehensive Antibody-Drug Conjugate (ADC) Services
Under the collaboration, Celltrion will delegate WuXi XDC as primary service provider on each of the integrated projects, from process development to GMP m...
January 24, 2024 | News
Kindeva Drug Delivery Acquires Summit Biosciences, a Nasal Drug Development Specialist
The acquisition of Summit enhances Kindeva’s existing drug-delivery capabilities by adding a new drug-delivery platform, further expanding Kindeva&rs...
January 19, 2024 | News
Eurofins CDMO Alphora Completes New Pilot Scale Biologics Facility
The facilities’ offerings include upstream and downstream development, process design, analytical development, GMP QC testing, GMP Cell-Based Assays,...
January 18, 2024 | News
Charles River Streamlines AAV Vector Manufacturing with Rep/Cap Plasmids Launch
Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf Rep/Cap plasmid offering, designed to streamline...
January 17, 2024 | News
Most Read
- Pioneering Precision: Top 15 Clinical and Lab Diagnostic Companies to Watch in 2025
- 2025 Pharma and Medical Device Trends for Manufacturing Leaders
- 25 High-Value Drugs Losing Patent Protection in 2025: What It Means for Healthcare
- BioPharma Trends 2025: 25 Key Insights Shaping Asia Pacific's Future
- Driving Oncology Forward: 25 Companies Redefining Antibody-Drug Conjugates (ADCs) in 2025
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Top Management Shakeups of 2024: Redefining Pharma, Biopharma, and Biotech Leadership
- James Park Joins South Korean LOTTE BIOLOGICS as New CEO to Lead Global Expansion
- Australia Takes the Lead: Moderna Opens Southern Hemisphere’s First mRNA Manufacturing Facility in Victoria
- Eli Lilly Announces $3 Billion Expansion in Wisconsin to Boost Global Medicine Production
- Ngee Ann Polytechnic Partners with Merck Singapore to Elevate Biopharmaceutical Education
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Life Sciences CEOs Bet Big on AI and Workforce Growth Despite Economic and Industry Headwinds
News
